Skip to main content
search
Conference

BioTechX EU

Conference: BioTechX EU

Date: October 6 - 8, 2025

Location: Basel, Switzerland

Booth: 250

Complex challenges in drug discovery and development are transformed by Certara’s scientific expertise, advanced biosimulation, and innovative technology. We are focused on helping our customers move their promising research forward faster — saving years of risk and time to bring new therapies from molecule to market with greater certainty. Learn how Certara is leading the way with model-informed drug development; uniting mechanistic, statistical and machine learning models with vast domain expertise in basic science, translation, clinical operations, and regulatory affairs.

Visit us at booth 250 to meet our teams in drug discovery, AI, and physiologically-based pharmacokinetics. You’ll learn how we’re empowering researchers to get to “first-in-human” faster, with predictive analytics in the design-make-test-analyze cycle all the way through biosimulation to understand ADME with little or no in vivo data.

Don't miss our two presentations

Monday, October 6
12:05
Cheminformatics Track

Where do we even start? Best practices and common themes in migrating compound registration systems

Dóra Barna, Director of Application Science, Chemaxon
As the pharmaceutical and biotech industries increasingly adopt AI and other in silico approaches, a growing number of organizations recognize that establishing a robust data foundation is a critical first step. This often involves modernizing legacy IT systems – particularly chemical registration solutions – and migrating historical R&D data to create a reliable “single source of truth.”
However, replacing or implementing a major enterprise software system, such as a registration platform, can be a complex and intimidating endeavor. In this presentation, we will explore practical strategies to make these migrations more manageable. Drawing on insights from past projects, we will highlight typical approaches, key focus areas, and best practices that help navigate this transformation with confidence.
Dóra Barna

Director of Application Science, Chemaxon

Dóra Barna is the Application Scientist Director of Chemaxon, a cheminformatics software company. Dóra received her PhD in Theoretical and Computational Chemistry in 2013 at the University of Szeged, Hungary. Since joining Chemaxon in 2012, she has held a variety of customer-facing technical roles, where she provided scientific and technical expertise and designed and delivered tailored cheminformatics solutions for key partners in the pharmaceutical and life science industries. In her current role, Dóra leads Chemaxon’s global team of application scientists and oversees the company’s technical presales strategy and execution.
Tuesday, October 7
14:55
Bioinformatics + InSilico R&D Track

Predicting First-in-Human PK: From Chemical Structure to PBPK

Chara Litou, PhD, Senior PBPK Consultant, Certara

Could a SMILES string alone help us predict in vivo pharmacokinetics? Equipped with the right PhysChem property predictors and a physiologically-based model of PK, discovery and translational scientists can now look ahead to animal and human ADME from the earliest stage of compound design. Explore the existing tools and what’s on the horizon with Chara Litou, PhD, Senior PBPK Consultant at Certara.

Chara Litou, PhD

Senior PBPK Consultant, Certara

Chara is a Senior PBPK Consultant at Certara with extensive experience in PBPK-PD, clinical pharmacology, and translational pharmacokinetics. She is skilled in DMPK and clinical activities, biopredictive in vitro testing, and formulation development. Her work focuses on predicting the in vivo performance of drugs and drug products from early discovery through to market approval.

Resources

Meet us there

Connect with us before the conference! Submit the short form below and we’ll contact you with a plan to meet in Basel.


You May Also Like

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions FasterPress Release

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster

The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscapeWebinar

The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape

Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor ConferencesPress Release

Certara to Participate in Upcoming Investor Conferences